

# Accelerating progress towards the United Nations' 90-90-90 target: The impact of a province-wide HIV Treatment-as-Prevention-based initiative in British Columbia, Canada

Ni Gusti Ayu Nanditha,<sup>1,2</sup> Xinzhe Dong,<sup>1</sup> Hiwot M. Tafessu,<sup>1</sup> Huimin Lu,<sup>1</sup> Rolando Barrios,<sup>1</sup> Julio S.G. Montaner,<sup>1,2</sup> Viviane D. Lima,<sup>1,2</sup>

<sup>1</sup> British Columbia Centre for Excellence in HIV/AIDS, Vancouver - Canada <sup>2</sup> University of British Columbia, Faculty of Medicine, Vancouver - Canada

## Introduction

“HIV Treatment as Prevention” (TasP), the scaling-up of testing followed by the immediate initiation of ART, is a strategy for reducing AIDS-related morbidity and mortality, and the spread of HIV. In British Columbia (BC), Canada, TasP was implemented under the Seek and Treat for Optimal Prevention of HIV/AIDS initiative (STOP) starting in 2010.

**Objective:** To compare the time from HIV diagnosis to antiretroviral therapy (ART) initiation (time Dx-Tx), and from ART initiation to first virologic suppression (time Tx-Vx) before and after the implementation of STOP.

## Methods

**Design:** population-based retrospective cohort study

**Data:** longitudinal individual-level from STOP cohort

**Study population:** all diagnosed people living with HIV (PLWH) in BC, who were ≥18 years old, ART naïve, and newly diagnosed in BC between 2005 and 2016

**Outcomes:** time Dx-Tx & time Tx-Vx

**Exposures:** HIV diagnosis & ART initiation eras, each grouped into pre-STOP (2005-2009) and post-STOP (2010-2016)

**Statistical analysis:** negative binomial regressions modelled the effect of STOP on the time Dx-Tx and time Tx-Vx, adjusting for confounders




Figure 1. The distribution of time Dx-Tx and time Tx-Vx (in months) among PLWH in BC from 2005-2016

## Results

- PLWH diagnosed before (N=1601) and after STOP HIV/AIDS (N=1700) were significantly different, e.g., 30% vs. 15% ever injected drugs, and the median CD4 level at diagnosis 280 vs. 380 cells/ $\mu$ L
- From 2005 to 2016, median time Dx-Tx and time Tx-Vx decreased substantially (Figure 1)
- After STOP, time Dx-Tx decreased by as much as 22 months among PLWH aged <30 years, but time Tx-Vx remained the longest among PLWH who live in BC's most rural health authority and had history of injection drug use (Figure 2)
- Controlling for confounders including changes in ART eligibility and first-line ART preferences, STOP was associated with a 65% shorter time Dx-Tx (adjusted mean ratio: 0.35 [95%CI: 0.32-0.38]) and a 22% shorter time Tx-Vx (0.78 [0.72-0.85])

## Discussion

In our large population-based cohort with universal health coverage, a TasP-based intervention was significantly associated with early ART initiation and faster time to virologic suppression, thus accelerating progress towards the United Nations' 90-90-90 target.

Our results support the global and equitable expansion of TasP to accelerate the control of HIV/AIDS, as currently recommended by the United Nations.

**Funding:** JSGM's TasP research, paid to his institution, has received support from the Public Health Agency of Canada, and the British Columbia Ministry of Health. VDL is funded by grants from the Canadian Institutes of Health Research (PJT-148595 and PJT-156147), and the Canadian Foundation for AIDS Research (CANFAR Innovation Grant – 30-101). NGAN is supported by the University of British Columbia's Four-Year Doctoral Fellowship

**Disclaimer:** All inferences, opinions, and conclusions drawn in this poster are those of the authors, and do not reflect the opinions of policies of the Data Stewards or funders.

**Lead Author Contact:** dnanditha@bccfe.ca | +1-778-926-0988




Figure 2. The distribution of time from HIV diagnosis to ART initiation and from ART initiation to viral suppression (in months) before and after STOP HIV/AIDS roll-out, stratified by selected demographic and clinical characteristics



BRITISH COLUMBIA  
CENTRE for EXCELLENCE  
in HIV/AIDS



EMBA  
CENTRE for EXCELLENCE  
in HIV/AIDS



Providence  
HEALTH CARE



NIH  
National Institutes  
of Health



CIHR IRSC



BRITISH  
COLUMBIA



Ministry of  
Health



UBC



CANADIAN  
FOUNDATION  
FOR AIDS  
RESEARCH